Rohto Pharmaceutical maintains full-year operating income forecast at JPY 45 billion

PUBT · 1d ago
Rohto Pharmaceutical maintains full-year operating income forecast at JPY 45 billion
  • Rohto Pharmaceutical maintained sales guidance of JPY 372.3 billion, up 8.3%, for the fiscal year ending March 2027.
  • Operating income remains forecast at JPY 45 billion, up 9.4%.
  • The sales outlook was raised for Asia but lowered for the Americas due to reduced eye drop shipments.
  • April-September 2026 sales rose 9% to JPY 179 billion, with growth across all regions.
  • First-half operating income increased 8.5% to JPY 20.9 billion, supported by Asian and European growth alongside improved profitability in Japan.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rohto Pharmaceutical Co. Ltd. published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.